STOCK TITAN

Aimei Health Technology Co., Ltd. (AFJK) SEC Filings

AFJK NASDAQ

Aimei Health Technology Co., Ltd. filings document the regulatory record of a Cayman Islands blank-check company with ordinary shares, units and rights registered for Nasdaq trading. The filings describe SPAC mechanics such as trust-account funding, redemption-related timelines, deadline extensions, shareholder voting procedures and amendments to governing documents.

Recent 8-K, proxy and late-filing records also disclose direct financial obligations, unsecured promissory notes used to fund extension payments, capital-structure terms, material agreements, Nasdaq listing-compliance notices, delayed annual-report reporting and governance matters associated with the company's initial business-combination process.

Rhea-AI Summary

Aimei Health Technology Co., Ltd. (AFJK) entered into a non-binding letter of intent with Hera Health Solutions Inc. for a proposed business combination. Under the LOI, Aimei would acquire 100% of Hera’s outstanding equity and equity equivalents in exchange for shares of the combined public company.

The LOI is non-binding on the proposed transaction, except for provisions including confidentiality and exclusivity. The transaction remains subject to definitive agreements, due diligence, required regulatory and shareholder approvals, and other customary closing conditions. Aimei expects to provide further details after execution of a definitive business combination agreement. Hera is developing drug-delivery technologies, including biodegradable nanofiber scaffolds and AI-driven formulation capabilities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

Aimei Health Technology Co., Ltd. (AFJK) reported a $68,552 net loss for the nine months ended September 30, 2026, versus net income of $961,651 a year earlier. Third-quarter net loss was $30,848, compared with net income of $352,019 in 2025; nine-month Trust Account interest of $330,527 was below general, administrative and operational costs of $399,079.

AFJK terminated its United Hydrogen business combination agreement on July 7, 2026; the required China Securities Regulatory Commission approval had not been granted as of July 6. On November 10, shareholders approved extending the business-combination deadline to December 6, 2027. Shareholders elected to redeem 841,629 shares for approximately $10.38 million, which remained unpaid as of issuance of the financial statements.

As of September 30, 2026, AFJK had $3,373 in bank cash, $12,739,616 in its Trust Account and a $4,076,789 working capital deficit. Management cited substantial doubt about the company's ability to continue as a going concern if it does not complete a business combination within the permitted period. Nasdaq notified AFJK that two listing-value measures were below their minimums, with a February 17, 2027 compliance deadline. AFJK also reported ineffective disclosure controls due to a material weakness.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.23%
Tags
quarterly report
-
Rhea-AI Summary

Aimei Health Technology Co., Ltd. (AFJK) deposited $34,330.96 into its trust account for public shareholders, extending its time to complete an initial business combination by one month, from November 6, 2026 to December 6, 2026. This is the 24th extension permitted under its amended and restated articles of association.

To fund the extension payment, the company issued an unsecured promissory note with principal of $34,330.96 to Aimei Investment Ltd. The note bears no interest and is due when the company completes a business combination. Aimei Investment Ltd. may convert all or part of the note into private units at $10.00 per unit immediately before completion, by giving written notice at least two business days before closing. Each unit consists of one ordinary share and a right to receive one-fifth of one ordinary share.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.08%
Tags
current report
Rhea-AI Summary

Aimei Health Technology Co., Ltd. (AFJK) extended the period to complete its initial business combination by one month, from October 6, 2026, to November 6, 2026, after $34,330.96 was deposited into its trust account for public shareholders. The company issued an unsecured, non-interest-bearing promissory note with principal of $34,330.96 to Aimei Investment Ltd. to fund the payment. The amendment removes a reference to United Hydrogen from the prior note description and leaves the other information unchanged.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
current report
-
Rhea-AI Summary

Aimei Health Technology Co., Ltd. (AFJK) seeks approval for Articles and trust-agreement amendments that would extend its business-combination period from 36 to 48 months, moving the deadline from December 6, 2026, to as late as December 6, 2027. If approved, each monthly extension requires the Sponsor to deposit the lesser of $80,000 for all outstanding Public Shares or $0.033 per outstanding Public Share. Shareholders also vote on MaloneBailey, LLP as auditor for the year ending December 31, 2026, and possible adjournment at the November 10, 2026 meeting.

The United Hydrogen transaction was terminated on July 7, 2026, because required China Securities Regulatory Commission approval had not been obtained as of July 6, 2026; AFJK says it is evaluating new targets. Approval of the Articles amendment would trigger an offer to redeem Public Shares; the estimated per-share redemption value was approximately $12.25 per Public Share as of October 2, 2026, with a November 6, 2026 tender deadline.

As of October 2, 2026, the Sponsor, directors, executive officers and affiliates beneficially owned and were entitled to vote 2,057,000 ordinary shares, approximately 64.96% of shares outstanding, and were expected to support all four proposals. The Articles amendment requires two-thirds of votes cast; each other proposal requires a simple majority.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
proxy
-
Rhea-AI Summary

Aimei Health Technology Co., Ltd. asks shareholders to approve an Articles amendment that would extend its business-combination deadline from December 6, 2026, to as late as December 6, 2027. A separate Trust Agreement amendment would align that agreement; the Articles change would allow up to 48 months from the December 6, 2023 IPO. If the Trust Agreement amendment is approved, each additional monthly extension would require the Sponsor to deposit the lesser of $80,000 for all outstanding Public Shares or $0.033 per outstanding Public Share. Contributions are due by the sixth of each succeeding month through November 6, 2027, bear no interest, and are repayable by Aimei Health to the Sponsor upon consummation of a business combination. At the November 10, 2026 meeting, shareholders also consider MaloneBailey, LLP as 2026 auditor and adjournment if votes are insufficient.

The request follows termination of the United Hydrogen agreement on July 7, 2026, after China Securities Regulatory Commission approval had not been obtained by July 6; Aimei Health says it is evaluating new targets. If the Articles amendment is approved, Public Shareholders may elect cash redemption at a price estimated at approximately $12.25 per share based on the Trust Account as of October 2, 2026. Tender and a written request are due by 5 p.m. Eastern on November 6, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
proxy
Rhea-AI Summary

Aimei Health Technology Co., Ltd. (AFJK) deposited $34,330.96 into its trust account for public shareholders, enabling a one-month extension of its initial business-combination deadline from October 6, 2026 to November 6, 2026. This is the 23rd extension permitted under its amended and restated articles.

To fund the payment, Aimei issued an unsecured, non-interest-bearing promissory note with $34,330.96 principal to Aimei Investment Ltd. The principal is due when Aimei consummates its business combination with United Hydrogen. Aimei Investment may convert all or part of the note into private units at $10.00 per unit immediately before closing, by providing written notice at least two business days before closing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.86%
Tags
current report
-
Rhea-AI Summary

Aimei Health Technology Co., Ltd. (AFJK) extended the deadline to complete its initial business combination by one month, making a payment of $34,330.96 into its trust account to move the Termination Date from September 6, 2026 to October 6, 2026. This amount represents the lesser of $80,000 for all outstanding public shares and $0.033 per outstanding public share for the monthly extension and is the 22nd extension permitted under its Amended and Restated Articles of Association.

To fund the extension payment, the company issued an unsecured Promissory Note for $34,330.96 to Aimei Investment Ltd. The note bears no interest and becomes due upon consummation of the planned business combination with United Hydrogen. The payee may convert the note into private units at $10.00 per unit, each unit consisting of one ordinary share and one right to receive one-fifth of one ordinary share, immediately prior to closing by giving two business days’ written notice.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.08%
Tags
current report
-
Rhea-AI Summary

Aimei Health Technology Co., Ltd. (AFJK) reports that Nasdaq has notified it that its Market Value of Listed Securities (MVLS) has been below $50,000,000 and its Market Value of Publicly Held Shares (MVPHS) has been below $15,000,000 for the last 30 consecutive business days, violating Nasdaq Global Market continued listing standards.

The company has two separate 180-day compliance periods, through February 17, 2027, to have MVLS at or above $50,000,000 and MVPHS at or above $15,000,000 for at least 10 consecutive business days. AFJK’s shares continue to trade on the Nasdaq Global Market, but failure to regain compliance could lead to delisting or a transfer to the Nasdaq Capital Market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
current report
Rhea-AI Summary

Aimei Health Technology Co., Ltd., a SPAC focused on healthcare innovation, reported a small net loss of $37,704 for the six months ended June 30, 2026, as general, administrative and operational costs of $254,332 exceeded $216,628 of interest income on cash held in its trust account.

Assets totaled $12.53 million, including $12.49 million in the Trust Account and only $1,466 of operating cash, alongside a working capital deficit of $3.79 million and $2.20 million of related-party extension loans. As of June 30, 2026, 1,040,332 public shares were classified as redeemable at $12.00 per share, with an additional 2,126,000 non-redeemable ordinary shares outstanding.

The company terminated its previously agreed Business Combination Agreement with United Hydrogen on July 7, 2026, so that transaction will not close, and it continues to search for a new target. Management disclosed substantial doubt about the ability to continue as a going concern if no business combination is completed by the extended deadline, and also reported a material weakness in internal controls related to inadequate segregation of duties and insufficient written procedures.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
quarterly report

FAQ

How many Aimei Health Technology Co., Ltd. (AFJK) SEC filings are available on StockTitan?

StockTitan tracks 36 SEC filings for Aimei Health Technology Co., Ltd. (AFJK), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Aimei Health Technology Co., Ltd. (AFJK)?

The most recent SEC filing for Aimei Health Technology Co., Ltd. (AFJK) was filed on November 17, 2026.